Patients infected with this genotype respond well to IFN-based regimens, with response rates approaching 80% in patients without cirrhosis, although the response is greatly reduced in those with advanced fibrosis.11, 12 SOF is active against HCV genotype 3 and in combination with the pan-genotypic NS5a inhibitor velpatasvir,9 >90% of patients respond. The gene discussed is IFNA1; the disease is Cirrhosis.